ACE2 and COVID-19: One month post-third dose, wild-type-specific ACE2 displacement activity in COVID-19-naive PWH was a median 99.6% (IQR 98.7–99.8%) compared with 99.1% (IQR 97–99.6%) in controls (univariable P = 0.002; Fig. 2a), though this did not remain significant after multivariable adjustment (not shown).